On August 1, 2023 Recently, a researcher at Children’s Hospital Los Angeles developed a new way to diagnose retinoblastoma by sampling the fluid at the front of the eye (Press release, Children’s Hospital Los Angeles, AUG 1, 2023, View Source [SID1234633615]). These liquid biopsies also offer genetic and chromosomal information, which gives a more complete picture of each child’s disease. Now CHLA will lead an international liquid biopsy retinoblastoma study, the first of its kind.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jesse Berry, MD, is the Director of Ocular Oncology and the Retinoblastoma Program at CHLA. Once strictly a clinician, Dr. Berry transitioned to research with the goal of finding a better way to diagnose retinoblastoma. This cancer—which affects the light-sensing layer at the back of the eye—is extremely aggressive and can result in loss of one or both eyes if not treated quickly. But timely treatment depends on a timely and accurate diagnosis.
Most cancers are diagnosed with a biopsy: An oncologist samples tumor cells and performs various tests to confirm the type of cancer. Unfortunately, this cannot be done with retinoblastoma. "It isn’t a solid mass, like some cancers," says Dr. Berry. "It’s like a thick liquid, and it’s difficult to physically get to." Attempts to directly biopsy the tumor, she explains, can do more harm than good, potentially causing cancer cells to spread. Not only does this make diagnosing the cancer difficult, but it also prevents researchers from studying the cancer cells, a necessary process in understanding the disease and advancing treatments. Dr. Berry had the idea to examine the aqueous humor, the fluid inside the eye itself.
"The last five years have been really exciting in retinoblastoma research," says Dr. Berry. "We use a tiny amount of fluid—100 microliters, about half the size of a green pea—and from that we get a trove of information, things that were impossible to see before. We can see genetic mutations, chromosomal aberrations. We can diagnose retinoblastoma at a molecular level." This provides oncologists with a very specific map of each child’s disease.
"There are a few specific factors that come up in these biopsies," she says, "markers that we suspect are bad players, leading to a more severe disease." Indeed, this is what Dr. Berry has confirmed in studies involving CHLA patient samples. "But we need to really ramp up this research so we can help kids everywhere," says Dr. Berry. "We need to look at a much larger data set." This summer, Dr. Berry’s team will do just that, leading an international research study.
The National Cancer Institute of the National Institutes of Health (NIH) has awarded Dr. Berry $2.8 million to lead the first prospective international retinoblastoma liquid biopsy study to date. The study will include samples from 18 centers, including the largest retinoblastoma center in Canada. All material will be processed and studied at Children’s Hospital Los Angeles, under the direction of Dr. Berry, who is the sole principal investigator named on the grant.
Children will be followed for a minimum of two years, so researchers can examine samples for possible cancer recurrence. Because tumors return in approximately 50% of retinoblastoma patients, this information can be lifesaving.
"We know that detecting a cancer as early as possible gives a child the best chance," says Dr. Berry. "In continuing to take biopsies from these children, we can treat any recurrences early on, even before they’re visible to a clinician upon examination."
The results of Dr. Berry’s forthcoming study will help shape the next phase of her research. "Right now, we’re in this position where we see very strong data," she says, "and we need to ensure that what we’re seeing is also represented in the international population." Then, says Dr. Berry, the team has plans to develop a clinical trial to evolve the standard of care for diagnosing and treating retinoblastoma—and link specific treatments to the information identified in the liquid biopsy.